0000891293-22-000047.txt : 20221006
0000891293-22-000047.hdr.sgml : 20221006
20221006162045
ACCESSION NUMBER: 0000891293-22-000047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221004
FILED AS OF DATE: 20221006
DATE AS OF CHANGE: 20221006
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 221298400
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-10-04
0
0000891293
CTI BIOPHARMA CORP
CTIC
0001276750
KIRSKE DAVID
C/O CTI BIOPHARMA CORP.
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
common stock
2022-10-04
4
M
0
1400
0.9489
A
18313
D
common stock
2022-10-04
4
S
0
1400
6.25
D
16913
D
common stock
2022-10-04
4
M
0
100
0.9489
A
17013
D
common stock
2022-10-04
4
S
0
100
6.26
D
16913
D
common stock
2022-10-04
4
M
0
609
0.9489
A
17522
D
common stock
2022-10-04
4
S
0
609
6.27
D
16913
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-10-04
4
M
0
1400
0
D
2029-02-19
Common Stock
1400
324967
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-10-04
4
M
0
100
0
D
2029-02-19
Common Stock
100
324867
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-10-04
4
M
0
609
0
D
2029-02-19
Common Stock
609
324258
D
This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.
David Kirske
2022-10-06